DexCom (DXCM)
(Delayed Data from NSDQ)
$72.36 USD
+2.31 (3.30%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $72.50 +0.14 (0.19%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
DXCM 72.36 +2.31(3.30%)
Will DXCM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DXCM
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
DexCom (DXCM) Q2 Earnings Surpass Estimates
CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings
Other News for DXCM
10 Health Care Stocks With Whale Alerts In Today's Session
Invesco Summit Fund Q2 2024 Review
QQQ ETF Update, 8/15/2024
RAMQ Expands Provincial Coverage to Include Dexcom G7, Bringing the Next-Generation CGM System to More Quebec Residents
Invesco American Franchise Fund Q2 2024 Review